Patents by Inventor Richard Heidebrecht

Richard Heidebrecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12162994
    Abstract: Described herein are compositions and methods for preparing hydrogel capsules using a cross-linking solution comprising a process additive. The process additive improves the quality of the resulting hydrogel capsules, such as increasing the number of defect-free capsules.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 10, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Lauren Emily Barney, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller
  • Patent number: 12161760
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 10, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • Publication number: 20240279187
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Application
    Filed: December 5, 2023
    Publication date: August 22, 2024
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Patent number: 11945786
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: April 2, 2024
    Assignee: SIGILON THERAPEUTICS, INC.
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Publication number: 20230303502
    Abstract: Described herein are compounds of Formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof, related compositions and preparations thereof, as well as methods of making and using the same.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 28, 2023
    Inventors: Richard Heidebrecht, Christopher P. Hencken, Omar De Paolis, Weiheng Wang, Matthew Buchanan
  • Publication number: 20230123802
    Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 20, 2023
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
  • Publication number: 20230045277
    Abstract: Described herein are compounds of Formula (I), polymers and implantable elements comprising compounds of Formula (II), and compositions and methods of use thereof. In particular, the compounds, modified polymers, implantable elements and related compositions may be used in methods for the prevention and treatment of a disease, disorder or condition in a subject.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 9, 2023
    Inventors: Elyse Bourque, Richard Heidebrecht, Christopher P. Hencken
  • Publication number: 20230003706
    Abstract: Described herein are methods for evaluating polymer compositions comprising polymers modified with a small molecule compound (e.g., afibrotic compound), including methods for determining the concentration levels of said compounds.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 5, 2023
    Inventors: Richard Heidebrecht, Zoe Yin
  • Publication number: 20220349896
    Abstract: Described herein are methods for evaluating polymer compositions comprising polymers modified with a polypeptide (e.g., a cell-binding polypeptide), including methods for determining polypeptide concentration.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 3, 2022
    Inventors: Richard Heidebrecht, Zoe Yin
  • Publication number: 20220267794
    Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 25, 2022
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
  • Publication number: 20220000789
    Abstract: Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same. The cells are capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 6, 2022
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
  • Publication number: 20210145759
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 20, 2021
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • Publication number: 20210145889
    Abstract: Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 20, 2021
    Inventors: Devyn McKinley Smith, David Peritt, Omid Veiseh, Richard Heidebrecht, Robert James Miller
  • Publication number: 20210060205
    Abstract: Described herein are compounds of Formula (I), modified polymers and implantable elements comprising compounds of Formula (II), as well as compositions and methods of use thereof. In particular, the compounds, modified polymers, implantable elements and related compositions may be used in methods for the prevention and treatment of a disease, disorder or condition in a subject.
    Type: Application
    Filed: March 1, 2019
    Publication date: March 4, 2021
    Inventors: Richard Heidebrecht, Robert James Miller, Omid Veiseh
  • Publication number: 20210002433
    Abstract: Described herein are compositions and methods for preparing hydrogel capsules using a cross-linking solution comprising a process additive. The process additive improves the quality of the resulting hydrogel capsules, such as increasing the number of defect-free capsules.
    Type: Application
    Filed: March 1, 2019
    Publication date: January 7, 2021
    Inventors: Lauren Emily Barney, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller
  • Publication number: 20200263196
    Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 20, 2020
    Inventors: Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Robert James Miller, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • Publication number: 20200039943
    Abstract: The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 6, 2020
    Inventors: Omid Veiseh, Richard Heidebrecht, Paul Kevin Wotton, Matthias Alexander Oberli, Robert James Miller
  • Publication number: 20190263810
    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Inventors: Ben C. ASKEW, Richard HEIDEBRECHT, Takeru FURUYA, Mark E. DUGGAN, D. Scott EDWARDS
  • Patent number: 8158825
    Abstract: The present invention relates to a novel class of modified malonate derivatives. The modified malonate compounds can be used to treat cancer. The modified malonate compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: April 17, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jonathan Grimm, Paul Harrington, Richard Heidebrecht, Jr., Thomas Miller, Karin Otte, Phieng Siliphaivanh, David Sloman, Matthew Stanton, Kevin Wilson, David Witter, Solomon Kattar, Paul Tempest
  • Patent number: 8119685
    Abstract: The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: February 21, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Richard Heidebrecht, Joey Methot, Dawn Mampreian, Thomas Miller, Phieng Siliphaivanh